Inner Banner image

Be a part of World Congress on Control & Prevention of HIV/AIDS & STDs-STIs

About Us


December 15-16, 2021 at 11:00 AM GMT 
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar


Abu Dhabi, UAE

We welcome all the Participants from all around the globe to be a part of "World Congress on Control & Prevention of HIV/AIDS & STDs - STIs " scheduled on December 15-16, 2021 at Abu Dhabi, UAE. The 2021 edition of the summit will move forward with the theme “Aiming for an HIV Free Society". HIV 2021 conference gathers noted Eminent Scientists/Research Professors, Junior's/Senior's analysers, Students, Doctors also researchers from World Health Societies & Associations and Medical Universities under one roof where networking and world partnering happens for the acceleration of future research.

World congress on Control & Prevention of HIV/AIDS, STDs - STIs is composed of many intriguing educational programs along with multiple panels, workshops, affinity cluster lunches, paper displays, and scientific sessions by professionals. Everybody being a part of this conference gets certification for his/her participation and a platform to reconstruct client base. We arrange to offer all delegates and great professors with all potential basic amenities and for attendees a source of information concerning all the upcoming technologies lined up.


Session 1: Sexual and Reproductive Health and HIV
HIV affects or potentially affects all the dimensions of women's sexual and reproductive health – pregnancy, childbirth, breastfeeding, abortion, use of contraception, exposure to, diagnosis and treatment of STIs and their exposure to sexual violence.
Session 2: Universal Access to HIV/AIDS Prevention, Treatment and Cancer
The WHO, along with UNICEF and UNAIDS Secretariat, has been issuing annual "Towards Universal Access" progress reports, monitoring key components of the worldwide health sector response to HIV, since 2006, when UN Member States committed to universal access to HIV prevention, treatment, care and support by 2010-20230. Based on the Progress Reports, the WHO and partners have been advocating for increased awareness on the need for continued progress in low- and middle-income countries, providing recommendations to overcome persisting challenges.
Session 3: Blood Transfusion Safety
Blood transfusions are needed for a wide range of health conditions including anemia, complications during pregnancy and childbirth, severe trauma due to accidents, and surgical procedures. They are also regularly used for patients with conditions such as sickle cell disease and thalassaemia and for products to treat hemophilia. Maintaining safe and effective procedures around the collection, storage and use of donated blood is essential. Collectively called hemovigilance, these procedures cover the entire blood transfusion chain and are used to standardize the use of blood in healthcare.
Session 4: Recent Advancement in Techniques Involved in HIV
The search for a preventive immunization that can stop the worldwide pandemic is a definitive objective of HIV research. Improvement of an immunization against HIV-1 has been tormented by numerous outlandish difficulties. Distinctive immunization ideas have been tried to conquer these difficulties. Trial immunizations that indicated guarantee in preclinical trials were progressed into clinical trials. However, human trials turned out to be an enormous dissatisfaction until the aftereffects of the RV144 trial in Thailand. Urine tests can be used to test for urethritis in both sexual orientations. Late urination will have washed gonorrheal discharge from the urethra. In this way, to accumulate sufficient discharge, pee tests should be taken no not as much as an hour after the patient's last pee. Vaginal swab illustrations are used to test for cervicitis. Gonorrheal cervicitis produces a satisfactory discharge that swabs require not be taken by speculum examination. Or maybe, they can be assembled unpredictably by the patient herself.
Session 5: HIV /AIDS and Retro Viral Disease
Retroviruses induce diseases that do not fit easily into any of the major categories and different tissues can influence the type of disease that develops the first retrovirus associated with disease was equine infectious anemia virus (EIAV). BFU-E and CFU-E contained by anemic cats is very less, and FeLV infection decreases the generation of these precursors in vitro. While murine retroviruses are inactivated by human complement and are not capable of causing human disease
Session 6: Evolution of HIV
Human Immunodeficiency Virus (HIV) originated in Central and West Africa in non-human primates and of two types: HIV-1 and HIV-2. HIV-1causes majority of HIV infections globally being more virulent and easily transmitted while HIV-2 which is less transmittable. According to researchers, HIV evolved from the closely related SIV which after post mutation transformed to humans from non-human primates as HIV in form of zoonosis. To determine relatedness, molecular phylogenetic process used to compare viral genomic sequences.
Session 7: HIV and Pregnancy
In the uterus, a baby can be infected with HIV. By taking treatments, the percentage of HIV infected babies born to women can be reduced to less and the treatment is received as a low viral load during pregnancy which can reduce the chances of passing HIV from mother to child during pregnancy and childbirth. The symptoms of HIV during pregnancy can be rapid weight loss, dry cough, night sweating, swollen lymph glands in the armpits or necks, unusual blemishes on the tongue, in throat or mouth, red or brown blotches on the skin, nose, mouth or eyelids.
Session 8: Living with HIV
As HIV often presents no physical symptoms, it is impossible by looking at someone to know if he or she is infected by HIV. From major reports of HIV positive people, the survival rate has improved. Now they can expect to live as long as someone who doesn’t have HIV by taking antiviral treatment, exercising regularly, eating healthily, managing stress & getting support and avoiding excessive alcohol drug use. Because, once HIV multiplies inside the host cells, his or her immune system will no longer be able to protect the body.
Session 9: AIDS Research and Therapy
Research on HIV generally aims at prevention, treatment as well as care of AIDS and other HIV related diseases. Research part includes decreasing the side effect of the medicines, further simplification of the drug structure as well as what treatment doctor should recommend for the HIV infected people. Therapy is generally for developing a healthy immune system to decrease the complication.
Session 10: STD, STIs and Infertility
Chlamydia and gonorrhea are major cause of pelvic inflammatory disease (PID) as well as infertility. Chlamydia can also lead to fallopian tube infection. PID can also cause pregnant damage to the fallopian tubes, uterus and surrounding tissues, which can lead to infertility. By prescribing oral antibiotics like azithromycin (Zithromax) and doxycycline, the infection can be clear up within two to three weeks’ Infertility.
Session 11: Gender Inequality and HIV
In Sub-Saharan Africa particularly, young girls and women are getting affected by HIV. Inequalities between the genders make girls more vulnerable and prone to HIV and other related diseases. These inequalities arise due to cultural, social as well as economic issues. In many cases, biased social and cultural norms are interpreted into laws which act as blockades to HIV services for women, increasing their helplessness to HIV.

Session 12: Progress for HIV Vaccine
HIV reproduces and mutates so fast, that antibodies produced against the virus quickly get ineffective against newer viruses. This is why stimulating antibody production cannot clear the infection. HIV has various sub-types like type-B, type-C etc. found in different region. The vaccine to be develop must be effective against all sub-types of HIV. RV144 vaccine is now being tested. Imbokodo is testing a prime-boost vaccine. Jassem tested a vaccine on 2600 women aged 18 to 35 and the results are expected by 2022.
Session 13: Preventing STD & STI
STD & STI can cause severe damage to the body, which can also result in death. These are caused by bacterial & viral infection. Especially teenagers and adult needs to take care the proper preventions and protection to avoid any disease related to this. Antiviral drugs are to be taken as a daily suppressive therapy with prescription. People with STDs or STIs should go for prevention and go for yearly checkup and test.
Session 14: SDG & AIDS Care
The goal of Sustainable Development for 2030 reflects the complexity of the modern life as well as the side effect of all these. As we all know HIV cannot be ended without addressing the issue of health and vulnerability. People living with this epidemic are often live-in fragile communities and are most affected by the inequality and discrimination. The SDG set the goal to end this and we all should be a part of that goal.
Session 15: Reproductive Health & Contraception
In choosing a method of contraception, dual protection from the simultaneous risk for HIV and other STDs also should be considered. Although hormonal contraceptives and IUDs are highly effective at preventing pregnancy, they do not protect against STDs, including HIV. Consistent and correct use of the male latex condom reduces the risk for HIV infection and other STDs, including chlamydial infection, gonococcal infection, and trichomoniasis.
Session 16: A World without HIV
With speedy implementation of effective prevention and treatment tools we have achieved a lot of reduction in cases related to HIV, STD as well as STI. However, given the range of the epidemic we need to look for the effective and safe HIV vaccine.  Also providing a realistic and cost-effective means of treatment for the whole population will be a great achievement. We all should work towards a world without HIV and diseases resulting out of it.

Importance and Scope:

Theme of the conference “Aiming for a HIV Free Society” conveys the essential notion that we tend to showcase to the planet. HIV 2021 prioritizes the high quality researches and technologies used for human health, welfare and convenience. Folks from each genre i.e. the extremely classified professionals, scientists,  researchers and young innovators have an excellent deal during this as they will be having an opportunity for diversification and world communication. We tend to believe HIV 2020 can start up as a seminar study and a platform jam-packed with public awareness.

Business worth of HIV:

In June 1981, scientists reported the first clinical evidence of a disease known as acquired immunodeficiency syndrome, or AIDS. Its cause, the human immunodeficiency virus (HIV), was acknowledged in 1983. Since the start of the epidemic in 1981, around 75 million have become infected with HIV and around 32 million people have died of AIDS-related illnesses. In 2018, there were 37.9 million people living with HIV. New HIV infections have fallen by 16% since 2010 (by 41% among children) and AIDS-related deaths have fallen by 55% since the peak in 2004. The United Nation family has been in the forefront of this improvement. Ending AIDS by 2030 is an integral part of the Sustainable Development Goals (SDGs), which were unanimously adopted by United Nations Member States in 2015. HIV Treatment Access: in 2018, 23.3 million folks with HIV (62%) were accessing antiretroviral medical care (ART) globally, a rise of one.6 million since 2017 and up from eight million in 2010. Mother-to-Child Transmission: In 2018, ninety two of pregnant ladies with HIV received ART to stop transmission HIV to their babies throughout physiological state and childbearing and to shield their own health. This is often compared to forty ninth in 2010. AIDS-related Deaths: AIDS-related deaths are reduced by over fifty fifth since the height in 2004. In 2018, around 770,000 folk sided from AIDS-related diseases worldwide, compared to one.2 million in a pair of010 and one.7 million in 2004. Regional Impact: the overwhelming majority of individuals with HIV are in low- and middle-income countries. In 2018, there have been twenty.6 million folks with HIV (57%) in Japanese and southern continent, 5.0 million (13%) in western and Central African Republic, 5.9 million (16%) in Asia and therefore the Pacific, and 2.2 million (6%) in Western and Central Europe and North America

Funding for HIV:

• To finish AIDS as a public health threat by 2030, UNAIDS estimates that US$26.2 billion are going to be needed for the world HIV response in two020 alone. This implies the planet should increase the number of resources out there for HIV by US$1.5 billion every year between 2016 and 2020, a scenario that's wanting more and more unlikely.

• In recent years, high-income countries have reduced funding for the HIV response in low- and middle-income countries, with a seven-membered decrease according between 2015 and 2016. Philanthropic donations, on the opposite hand, have up for the past 3 consecutive years.

Universities related to HIV/AIDS Worldwide:


  • Augusta University
  • Wayne State University
  • Penn University
  • University of Maryland
  • Drexel University
  • University Of Miami
  • University of Georgia
  • Harvard University
  • Washington University
  • University of Illinois
  • University of Minnesota
  • University of Charleston
  • West Virginia University


  • University of Cambridge
  • University of Oxford
  • University of Copenhagen
  • University College London
  • Swiss Federal Institute of Technology Zurich
  • Imperial College London
  • University of Zurich
  • Karolinska Institute
  • University of Manchester
  • University of Munich
  • University of Edinburgh
  • Pierre and Marie Curie University
  • Catholic University of Leuven
  • Heidelberg University
  • University of Helsinki

Asia Pacific:

  • Osaka University
  • University of Tokyo
  • National University of Singapore
  • Kyoto University
  • Mahidol University
  • Tel Aviv University
  • University of Hong Kong
  • Keio University
  • Hebrew University of Jerusalem
  • Seoul National University
  • National Taiwan University
  • Sun Yat-sen University
  • Fudan University
  • Zhejiang University
  • Peking University

Middle East:

  • Alexandria University
  • Cairo University
  • American University of Kuwait
  • The Lebanese American University (LAU)
  • Weill Cornell Medical College in Qatar
  • Paris-Sorbonne University Abu Dhabi
  • Mohammed bin Rashid University of Medicine and Health Sciences
  • Hebrew University
  • King Saud bin Abdulaziz University for Health Sciences
  • King Saud University
  • Gulf Medical University
  • Sana'a University

HIV Related Association & Societies:


  • American Academy of HIV Medicine
  • American Sexual Health Association
  • Association of Nurses in AIDS Care
  • Association for Professionals in Infection Control and Epidemiology
  • International AIDS Society – USA
  • International AIDS Society
  • Infectious Diseases Society of America
  • British HIV Association
  • Australasian Society for HIV Medicine
  • HIV Medicine Association
  • International Association of Physicians in AIDS Care
  • National Medical Association
  • HIV Medicine Association


  • The European AIDS Clinical Society
  • Aids Hilfe Wien Austria
  • EATG (European AIDS Treatment Group) Belgium
  • Czech AIDS Help Society Czech Republic
  • AIDS Fondnet Denmark
  • Deutche AIDS-Hilfe / AIDS Action Europe Germany
  • Global Network of People Living with HIV Netherlands
  • ARAS - Romanian Association against AIDS Romania
  • Alliance Global Ukraine
  • European AIDS Treatment Group
  • HIV Pharmacy Association

Asia Pacific:

  • CARAM Asia
  • National AIDS Programme
  • National Center for HIV/AIDS, Dermatology and STDs
  • AIDS Concern
  • Hong Kong AIDS Foundation
  • The Society for AIDS Care
  • HIV Medicine Association of India
  • AIDS Clinical Center
  • Korean HIV/AIDS Prevention and Support Center
  • Taiwan Tongzhi Hotline Association

Middle East:

  • Egyptian AIDS Society
  • Egyptian Network of NGOs fighting AIDS
  • AIDS Research Center of Iran
  • HATAM - HIV/AIDS Treatment and Research Center
  • Pozitif Yasam Dernegi (Positive Living Association)
  • Saudi Charity Association for AIDS Patients
  • National AIDS Programme
  • Israel AIDS task force
  • National HIV/AIDS program

Funding bodies:

  • Centres for Disease Control (CDC)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Child Health and Human Development (NICHD)
  • NIH Office of AIDS Research (OAR)
  • Irish Aid
  • Elton john AIDS foundation
  • Mac AIDS fund
  • The global fund

The Road Ahead:

HIV market can see modest growth to $22.5 billion by 2025. The human immunological disorder virus (HIV) market across the 9 major countries of the USA, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China, is about to grow from $16.3 billion in 2015 to $22.5 billion by 2025, representing a compound annual rate of simply over three-dimensional, in step with Global Data, a recognized leader in providing business info and analytics.


HIV/AIDS 2021 through this learning experience dreams for a society where HIV infections are rare and when they do follow, all person, irrespective of age, gender, race/ethnicity, sexual orientation, gender identity or socio-economic circumstance, will have unrestricted access to high quality, life-extending care, free from disgrace and discrimination.



Young Scientist Awards at Control & Prevention of HIV/AIDS & STDs-STIs 2021 for the best researches in HIV/AIDS.

Meetings International is announcing Young Scientist Awards through Control & Prevention of HIV/AIDS & STDs-STIs Conference which is scheduled at Abu Dhabi, UAE during December 15-16, 2021. This HIV-AIDS-2021 conference focuses on Current Emerging Practices in Clinical and Experimental HIV-AIDS.

HIV-AIDS- 2021 and upcoming conferences will recognise participants who have significantly added value to the scientific community of Food science and provide them outstanding Young Scientist Awards. The Young Scientist Award will provide a strong professional development opportunity for young researches by meeting experts to exchange and share their experiences at our international conferences.

HIV-AIDS-2021 focuses mainly on Advancements in HIV Infection, Treatment, and Advancements in HIV Drugs and many more. HIV-AIDS- 2021 conference operating committee is providing a platform for all the budding young researchers, young investigators, post-graduate/Master students, PhD. students and trainees to showcase their research and innovation.


Young Scientists, faculty members, post-doctoral fellows, PhD scholars and bright Final Year MSc and M.Phil. Candidates. Persons from Scientific Industry can also participate.

Benefits: The Young Scientist Feature is a platform to promote young researchers in their respective area by giving them a chance to present their achievements and future perspectives.

Acknowledgement as YRF Awardee

Promotion on the conference website, Young Researcher Awards and certificates

Meet Experts

Global Networking

Learning In a New Space

New Tips & Tactics